scispace - formally typeset
Z

Zexian Liu

Researcher at Sun Yat-sen University

Publications -  140
Citations -  12033

Zexian Liu is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 36, co-authored 110 publications receiving 9157 citations. Previous affiliations of Zexian Liu include Huazhong University of Science and Technology & University of Minnesota.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

HemI: a toolkit for illustrating heatmaps.

Wankun Deng, +4 more
- 05 Nov 2014 - 
TL;DR: An easy-to-use tool named HemI (Heat map Illustrator), which can visualize either gene or protein expression data in heatmaps and provides multiple clustering strategies for analyzing the data.
Journal ArticleDOI

GPS-SUMO: a tool for the prediction of sumoylation sites and SUMO-interaction motifs

Qi Zhao, +9 more
- 01 Jul 2014 - 
TL;DR: A new tool called GPS-SUMO was developed for the prediction of both sumoylation sites and SUMO-interaction motifs (SIMs) in proteins, and was demonstrated to be substantially superior against other existing tools and methods.
Journal ArticleDOI

LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer

Yun Wang, +21 more
- 02 Dec 2019 - 
TL;DR: LINRIS is an independent prognostic biomarker for CRC and the LINRIS-IGF2BP2-MYC axis promotes the progression of CRC and is a promising therapeutic target.
Journal ArticleDOI

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.

Feng Wang, +6 more
- 01 Oct 2019 - 
TL;DR: In this paper, a cohort study analyzes the medical records of 47 721 patients with various cancer types with POLE/POLD1 mutations to evaluate whether the mutations were associated with immunotherapy outcomes.